David Feldman
Publications
- Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation. Gene. 2013; (2): 554-9
- Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr Pract. 2012 Sep-Oct; (5): e114-20
- Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate. 2012; (15): 1628-37
- Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012; (6): 2576-87
- Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention. J Steroid Biochem Mol Biol. 2012
- Genetic disorders and defects in vitamin D action. Rheum Dis Clin North Am. 2012; (1): 93-106
- Relations between obesity, insulin resistance, and 25-hydroxyvitamin D. Am J Clin Nutr. 2012; (5): 1055-9
- The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids. 2012; (11): 1107-12
- The role of the vitamin D receptor and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3. Mol Endocrinol. 2012; (4): 574-82
- The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am. 2012; (1): 161-78
- Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol. 2011; (22): 3078-84
- Hereditary vitamin D-resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor. J Bone Miner Res. 2011; (11): 2710-8
- Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm Cancer. 2011; (3): 190-202
- Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011: 311-36
- Report of two unrelated patients with hereditary vitamin D resistant rickets due to the same novel mutation in the vitamin D receptor. J Pediatr Endocrinol Metab. 2011; (9-10): 793-9
- Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D(3) analogues hydroxymethylated at C-26. J Med Chem. 2011; (11): 3950-62
- The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃. Best Pract Res Clin Endocrinol Metab. 2011; (4): 593-604
- The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011; (1-2): 90-6
- Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol. 2011; (1-2): 61-9
- Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am. 2010; (2): 333-46, table of contents
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Mol Genet Metab. 2010; (1): 72-9
- Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010; (1): R19-38
- Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J Steroid Biochem Mol Biol. 2010; (1-2): 164-8
- The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2010; (2): 77-84
- The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am. 2010; (2): 401-18, table of contents
- Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010; (1): 32-42
- Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene. J Pediatr Endocrinol Metab. 2010; (8): 843-50
- Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol. 2010; (1-2): 343-8
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets in a Pomeranian dog caused by a novel mutation in the vitamin D receptor gene. J Vet Intern Med. 2009 Nov-Dec; (6): 1278-83
- A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009; (9): 3605-10
- Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia. J Bone Miner Res. 2009; (4): 643-51
- Hereditary vitamin D resistant rickets: identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. Bone. 2009; (4): 743-6
- Inactivation of the human vitamin D receptor by caspase-3. Endocrinology. 2009; (2): 679-86
- Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer. 2009; (9): 2050-9
- Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol. 2009; (1): 7-11
- Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Endocrinology. 2009; (4): 1580-7
- Modulation of vitamin d receptor activity by the corepressor hairless: differential effects of hairless isoforms. Endocrinology. 2009; (11): 4950-7
- Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate. 2009; (7): 719-26
- Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009; (5): 417-37
- Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys. 2008; (3): 935-40
- The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer. 2008; (3): 558-66
- A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Arch Biochem Biophys. 2007; (2): 285-92
- Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr. 2007; (1 Suppl): 205S-210S
- Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res. 2007: V74-80
- Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions. J Biol Chem. 2007; (35): 25231-9
- Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007; (3-5): 694-702
- Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Nutr Rev. 2007; (8 Pt 2): S121-3
- Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev. 2007; (8 Pt 2): S113-5
- Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res. 2006 Jul-Aug; (4A): 2525-30
- Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther. 2006; (6): 1539-49
- Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Endocrinology. 2006; (10): 4599-607
- Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther. 2006; (8): 2078-85
- Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006; (8): 4516-24
- Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Urology. 2006; (5): 1001-6
- Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control. 2006; (10): 1237-44
- Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs. J Bone Miner Res. 2005; (9): 1680-91
- Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol. 2005; (1-2): 49-61
- Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol. 2005; (1-2): 31-6
- Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol. 2005; (3): 872-6; discussion 876
- Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005; (17): 7917-25
- A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res. 2004; (6): 1018-24
- Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004; (3): 243-51
- Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology. 2004; (11): 5106-14
- Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol. 2004; (5): 1109-19
- Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol. 2004; (4): 307-15
- Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol. 2004; (1-2): 67-74
- Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004; (3): 131-41
- Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev. 2004; (8): 1325-30
- A low-calcemic vitamin D analog (Ro 25-4020) inhibits the growth of LNCaP human prostate cancer cells with increased potency by producing an active 24-oxo metabolite (Ro 29-9970). Recent Results Cancer Res. 2003: 349-52
- Hereditary 1,25-Dihydroxyvitamin D-resistant rickets. Endocr Dev. 2003: 175-99
- Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem. 2003; (2): 363-71
- Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr. 2003; (7 Suppl): 2461S-2469S
- The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer. 2003; (2): 131-40
- The role of vitamin D in prostate cancer. Recent Results Cancer Res. 2003: 205-21
- Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003; (1): 49-62
- Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev. 2003; (1): 23-7
- A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002; (5): 1889-900
- A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol Endocrinol. 2002; (11): 2538-46
- A novel nonsense mutation in the ligand binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. Mol Genet Metab. 2002; (4): 314-8
- Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol. 2002; (4 Pt 1): 1583-8
- The role of vitamin D in prostate cancer. Steroids. 2001 Mar-May; (3-5): 293-300
- A new enzyme-linked immunosorbant assay for the measurement of human vitamin D receptor. Bone. 2001; (3): 319-26
- A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets. Mol Genet Metab. 2001; (2): 138-48
- Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 2001; (1): 29-37
- Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 2001; (4): 1319-24
- Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Urology. 2001; (2 Suppl 1): 123-6
- Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001; (7): 2852-6
- Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001; (8): 3568-73
- The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; (1): 34-45
- 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol. 2000; (1-2): 133-43
- 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res. 2000; (8): 3371-9
- 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology. 2000; (7): 2548-56
- Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000; (6): 703-6
- Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology. 1999; (3): 1205-12
- Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999; (5): 2071-6
- PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. Biochem Biophys Res Commun. 1999; (3): 718-22
- Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol. 1999; (6): 2192-9
- Vitamin D resistance. Am J Med. 1999; (3): 355-70
- Vitamin D, parathyroid hormone, and calcium: a complex regulatory network. Am J Med. 1999; (6): 637-9
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor. J Bone Miner Res. 1998; (2): 259-64
- Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: the OFELY study. J Bone Miner Res. 1998; (1): 31-5
- The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res. 1998; (11): 1691-9
- Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol. 1998; (6): 2035-9; discussion 2039-40
- Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. Biochem Biophys Res Commun. 1998; (3): 467-73
- 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. Endocrinology. 1997; (1): 12-8
- 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 1997; (8): 3290-8
- Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. Mol Endocrinol. 1997; (3): 366-78
- Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest. 1997; (2): 297-304
- The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J Bone Miner Res. 1997; (7): 1043-8
- Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. J Bone Miner Res. 1997; (2): 234-40
- Vitamin D. Academic Press, Inc., San Diego. 1997
- A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab. 1996; (7): 2564-9
- Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate. 1996; (1): 20-9
- Simian virus 40-, but not human papillomavirus-, transformation of prostatic epithelial cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D-3. Int J Oncol. 1996; (1): 41-7
- The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res. 1996; (12): 1850-5
- Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D(3) on prostatic epithelial cells. Urol Oncol. 1995 Sep-Oct; (5): 188-94
- Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995; (1): 20-6
- Estrogens in unexpected places: possible implications for researchers and consumers. Environ Health Perspect. 1995: 129-33
- Oestrogen-binding protein in Candida albicans: antibody development and cellular localization by electron immunocytochemistry. Microbiology. 1995: 2685-92
- Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Endocrinology. 1995; (2): 705-12
- Vitamin D and prostate cancer. Adv Exp Med Biol. 1995: 53-63
- ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol. 1994; (1): 67-73
- Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; (3): 805-10
- Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. Proc Natl Acad Sci U S A. 1994; (3): 922-6
- Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J Clin Endocrinol Metab. 1994; (2): 313-6
- Inhibition of aldosterone synthesis in rat adrenal cells by nicotine and related constituents of tobacco smoke. Endocrinology. 1994; (5): 2171-7
- Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology. 1993; (6): 2279-86
- Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid-binding protein. Proc Natl Acad Sci U S A. 1993; (5): 1902-6
- Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology. 1993; (4): 1808-14
- Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; (5): 1952-60
- Chronic atypical seizure disorder and cataracts due to delayed diagnosis of pseudohypoparathyroidism. West J Med. 1992; (1): 64-5
- Cloning and characterization of the gene encoding the ADP-ribosylation factor in Candida albicans. Gene. 1992; (1): 123-8
- Cyclic adenosine 3',5'-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. Mol Endocrinol. 1992; (2): 198-206
- Activation of protein kinase-C inhibits vitamin D receptor gene expression. Mol Endocrinol. 1991; (4): 605-12
- Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg. 1991; (2): 204-8
- Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors. J Bone Miner Res. 1991; (10): 1099-107
- Hereditary 1,25-dihydroxyvitamin D resistant rickets: molecular basis and implications for the role of 1,25(OH) 2D3 in normal physiology. Mol Cell Endocrinol. 1990; (3): C57-62
- The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. J Clin Invest. 1990; (6): 2071-9
- Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab. 1989; (2): 263-9
- Characterization of an estrogen-binding protein in the yeast Candida albicans. Endocrinology. 1989; (4): 1965-72
- Sequence and expression of human myosin alkali light chain isoforms. Mol Cell Biochem. 1989; (2): 119-36
- Steroid metabolism as a mechanism of escape from progesterone-mediated growth inhibition in Trichophyton mentagrophytes. J Biol Chem. 1989; (19): 11186-92
- Dermatophyte-hormone relationships: characterization of progesterone-binding specificity and growth inhibition in the genera Trichophyton and Microsporum. J Clin Microbiol. 1988; (10): 2110-5
- Modulation of 1,25-dihydroxyvitamin D3 receptor binding and action by sodium butyrate in cultured pig kidney cells (LLC-PK1). J Bone Miner Res. 1987; (2): 151-9
- Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology. 1986; (3): 1119-26
- The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses. Endocrinology. 1986; (1): 250-9
- Characterization of an estrogen-binding protein in the yeast Saccharomyces cerevisiae. J Biol Chem. 1984; (6): 3450-6
- Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids. Endocrinology. 1984; (4): 1577-83
- Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984; (22): 1415-21
- Modulation of PTH-stimulated cyclic AMP in cultured rodent bone cells: the effects of 1,25(OH)2 vitamin D3 and its interaction with glucocorticoids. Calcif Tissue Int. 1984; (5): 580-5
- 1 alpha,25-dihydroxyvitamin D3 receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. J Biol Chem. 1983; (7): 4350-5
- Distribution of a corticosteroid-binding protein in Candida and other fungal genera. J Gen Microbiol. 1983; (8): 2379-85
- Effects of 1 alpha,25-dihydroxyvitamin D3 and glucocorticoids on the growth of rat and mouse osteoblast-like bone cells. Calcif Tissue Int. 1983; (6): 806-11
- Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. Proc Natl Acad Sci U S A. 1983; (24): 7659-63
- Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest. 1983; (1): 404-8
- Regulation of 1,25(OH)2 vitamin D3 receptor content in cultured LLC-PK1 kidney cells limits hormonal responsiveness. Biochem Biophys Res Commun. 1983; (1): 121-7
- Sulfoxide reductase activity of liver aldehyde oxidase. Biochim Biophys Acta. 1983; (1-2): 86-92
- 1,25-Dihydroxyvitamin D3 receptors and functions in cultured pig kidney cells (LLC PK1). Regulation of 24,25-dihydroxyvitamin D3 production. J Biol Chem. 1982; (5): 2504-8
- 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982; (3): 856-9
- An estrogen-binding protein and endogenous ligand in Saccharomyces cerevisiae: possible hormone receptor system. Science. 1982; (4569): 297-8
- Characterization of a unique corticosterone-binding protein in Candida albicans. J Biol Chem. 1982; (9): 4925-30
- Glucocorticoid regulation of 1,25(OH)2vitamin D3 receptors: divergent effects on mouse and rat intestine. Endocrinology. 1982; (4): 1400-2
- 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981; (3): 1083-6
- A corticosteroid binding protein and endogenous ligand in C. albicans indicating a possible steroid-receptor system. Nature. 1981; (5832): 477-9
- Regulation of 1,25-dihydroxyvitamin D3 receptors in cultured mouse bone cells. Correlation of receptor concentration with the rate of cell division. J Biol Chem. 1981; (11): 5561-6
- Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J Clin Endocrinol Metab. 1980; (6): 1463-5
- Demonstration of glucocorticoid receptors in the adrenal cortex: evidence for a direct dexamethasone suppressive effect on the rat adrenal gland. Endocrinology. 1980; (1): 137-46
- Heterogenetiy of glucocorticoid binders: a high affinity triamcinolone acetonide binder in bovine serum. Endocrinology. 1980; (5): 1370-75
- Nuclear translocation of the 1,25-dihydroxycholecalciferol receptor in mouse kidney. J Biol Chem. 1980; (16): 7510-3
- Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology. 1980; (6): 1916-22
- A receptor-like binding macromolecule for 1 alpha, 25-dihydroxycholecalciferol in cultured mouse bone cells. J Biol Chem. 1979; (16): 7491-4
- Characterization of a cytoplasmic receptor-like binder for 1 alpha, 25-dihydroxycholecalciferol in rat intestinal mucosa. J Biol Chem. 1979; (20): 10378-84
- Demonstration of a 1,25-dihydroxycholecalciferol cytoplasmic receptor-like binder in mouse kidney. J Clin Endocrinol Metab. 1979; (5): 798-800
- 19-Nor deoxycorticosterone (19-nor DOC): mineralocorticoid receptor affinity higher than aldosterone, electrolyte activity lower. Endocrinology. 1978; (4): 1514-7
- Is the glucocorticoid receptor identical in various target organs? J Steroid Biochem. 1978; (2): 141-5
- Receptor mediated glucocorticoid inhibition of protein synthesis in isolated bone cells. J Steroid Biochem. 1978; (3): 265-71
- Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology. 1977; (3): 619-28
- Glucocorticoid receptors in adipose tissue. Endocrinology. 1977; (2): 398-405
- 16Beta-hydroxydehydroepiandrosterone: the dichotomy between renal receptor binding and urinary electrolyte activity. Endocrinology. 1976; (2): 619-28
- Agonist and antimineralocorticoid activities of spirolactones. Am J Physiol. 1976; (1): 93-7
- Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention. J Clin Invest. 1976; (1): 1-7
- Autoradiographic localization of corticosterone receptors (type III) to the collecting tubule of the rat kidney. Endocrinology. 1975; (3): 505-16
- Cytoplasmic glucocorticoid binding proteins in bone cells. Endocrinology. 1975; (1): 29-36
- Steroidal 21-diazo ketones: photogenerated corticosteroid receptor labels. Biochemistry. 1975; (8): 1750-9
- Mineralocorticoid receptors and 18-hydroxydeoxycorticosterone binding in the kidney of the spontaneously hypertensive rat. Endocrinology. 1974; (4): 1185-8
- Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem Pharmacol. 1974; (10): 1493-501
- Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc Natl Acad Sci U S A. 1974; (4): 1431-5
- Evidence for a new class of corticosterone receptors in the rat kidney. Endocrinology. 1973; (5): 1429-41
- Glucocorticoid receptors in rat kidney: the binding of tritiated-dexamethasone. Endocrinology. 1973; (4): 1005-13
- The binding of 18-hydroxydeoxycorticosterone and 18-hydroxycorticosterone to mineralocorticoid and glucocorticoid receptors in the rat kidney. Endocrinology. 1973; (5): 1389-96
- Specific aldosterone binding in rat kidney and parotid. J Steroid Biochem. 1972; (2): 209-18
Help
Trial Administration